BAYN.DE

Bayer Aktiengesellschaft [BAYN.DE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BAYN.DE Stock Summary

Earnings have grown 15.1% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

BAYN.DE's dividend payments are well covered by cash flows with cash payout ratio of 64.3%.

Earnings are expected to fall -0.59% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

Profit margins (-0.08%) are lower than the previous year (0.08%)

BAYN.DE has less than 1 year of cash runway

Debt-to-Equity ratio of 1.45 is considered moderate, deeper research suggested.

Top 10 Correlated ETFs

BAYN.DE

Top 10 Correlated Stocks

BAYN.DE

In the News

BAYN.DE Financial details

Company Rating

Strong Buy

Market Cap

31.33B

Income

-3.67B

Revenue

47.78B

Book val./share

33.98

Cash/share

9.47

Dividend

2.4

Dividend %

7.52%

Employees

100.87K

Optionable

Shortable

Yes

Earnings

05 Mar 2024

P/E

-8.54

Forward P/E

7.37

PEG

0.18

P/S

0.66

P/B

0.94

P/C

3.37

P/FCF

-61.68

Quick Ratio

0.28

Current Ratio

1.13

Debt / Equity

1.45

LT Debt / Equity

1.44

EPS (TTM)

-3.73

EPS next Y

4.33

EPS next Q

1.24

EPS this Y

313.73%

EPS next Y

-215.96%

EPS next 5Y

-229.36%

EPS last 5Y

18.58%

Revenue last 5Y

5.09%

Revenue Q/Q

-6.36%

EPS Q/Q

142.19%

SMA20

-23.91%

SMA50

-32.45%

SMA100

-38.55%

Inst Own

Inst Trans

ROA

-3%

ROE

-10%

ROC

-0.01%

Gross Margin

58%

Oper. Margin

-1%

Profit Margin

-8%

Payout

-65%

Shs Outstand

982.42M

Shs Float

982.42M

Target Price

52W Range

30.22-65.66

52W High

-50.92%

52W Low

+6.33%

RSI

31.4

Rel Volume

1.15

Avg Volume

3.7M

Volume

4.26M

Perf Week

4.01%

Perf Month

-21.25%

Perf Quarter

-36.83%

Perf Half Y

-38.81%

Beta

0.99

Volatility

0.49%, 4.61%

Prev Close

0.22%

Price

31.9

Change

-1.39%

BAYN.DE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	42.08	44.36	42.14	44.87	51.65
Net income per share	1.8	2.48	-15.84	1.02	4.22
Operating cash flow per share	8.42	8.36	4.99	5.18	7.22
Free cash flow per share	5.66	5.66	2.53	2.52	4.22
Cash per share	4.61	5.5	12.1	7.88	10.33
Book value per share	48.87	48.22	31.07	33.61	39.47
Tangible book value per share	-30.55	-26.81	-31.97	-33.79	-25.35
Share holders equity per share	48.87	48.22	31.07	33.61	39.47
Interest debt per share	44.94	41.49	43.92	41.61	43.95
Market cap	57.25B	71.48B	47.31B	46.17B	47.48B
Enterprise value	93.87B	107.17B	84.67B	81.14B	83.62B
P/E ratio	33.78	29.41	-3.04	46.17	11.44
Price to sales ratio	1.45	1.64	1.14	1.05	0.94
POCF ratio	7.23	8.71	9.65	9.07	6.69
PFCF ratio	10.75	12.86	19.04	18.63	11.46
P/B Ratio	1.25	1.51	1.55	1.4	1.22
PTB ratio	1.25	1.51	1.55	1.4	1.22
EV to sales	2.37	2.46	2.05	1.84	1.65
Enterprise value over EBITDA	13.76	10.3	8.2	8.09	6.55
EV to operating cash flow	11.86	13.06	17.27	15.94	11.79
EV to free cash flow	17.63	19.29	34.07	32.74	20.18
Earnings yield	0.03	0.03	-0.33	0.02	0.09
Free cash flow yield	0.09	0.08	0.05	0.05	0.09
Debt to equity	0.88	0.82	1.36	1.2	1.07
Debt to assets	0.32	0.31	0.36	0.33	0.33
Net debt to EBITDA	5.37	3.43	3.62	3.49	2.83
Current ratio	1.36	1.4	0.97	1.11	1.08
Interest coverage	2.42	2.73	-1.84	5.18	3.37
Income quality	4.63	3.38	-0.32	4.98	1.7
Dividend Yield	0.04	0.04	0.06	0.04	0.04
Payout ratio	1.42	1.08	-0.18	1.99	0.48
Sales general and administrative to revenue	0.07	0.09	0.07	0.07	0.06
Research and developement to revenue	0.13	0.12	0.17	0.12	0.13
Intangibles to total assets	0.59	0.58	0.53	0.55	0.51
Capex to operating cash flow	-0.33	-0.32	-0.49	-0.51	-0.42
Capex to revenue	-0.07	-0.06	-0.06	-0.06	-0.06
Capex to depreciation	-0.41	-0.49	-0.18	-0.85	-0.45
Stock based compensation to revenue	0	0	0	0	0
Graham number	44.51	51.82	105.23	27.74	61.25
ROIC	0.03	0.05	-0.04	0.05	0.07
Return on tangible assets	0.03	0.05	-0.28	0.02	0.07
Graham Net	-75.35	-69.22	-70.22	-75.02	-70.24
Working capital	8.11B	9.34B	-1.07B	3.18B	2.68B
Tangible asset value	-28.74B	-26.32B	-31.41B	-33.2B	-24.91B
Net current asset value	-49.2B	-46.18B	-50.69B	-54.5B	-48.19B
Invested capital	0.88	0.82	1.36	1.2	1.07
Average receivables	7.18B	0	0	0	0
Average payables	5.27B	5.92B	6.05B	6.24B	7.17B
Average inventory	8.18B	10.3B	10.86B	11.11B	12.43B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	116.17	134.28	108.39	147.42	138.59
Days of inventory on hand	210.95	224.95	208.91	244.62	249.72
Receivables turnover	0	0	0	0	0
Payables turnover	3.14	2.72	3.37	2.48	2.63
Inventory turnover	1.73	1.62	1.75	1.49	1.46
ROE	0.04	0.05	-0.51	0.03	0.11
Capex per share	-2.76	-2.7	-2.46	-2.66	-3

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	11.48	12.21	14.65	11.24	10.53
Net income per share	0.56	0.62	2.22	-1.92	-4.65
Operating cash flow per share	2.7	3.12	-3.61	0.49	2.62
Free cash flow per share	1.96	1.77	-4.09	-0.12	1.93
Cash per share	9.24	10.33	8.12	7.77	9.47
Book value per share	42.01	39.47	41.6	37.61	33.98
Tangible book value per share	-28.48	-25.35	-21.98	-23.65	-23.92
Share holders equity per share	42.01	39.47	41.6	37.61	33.98
Interest debt per share	0.65	42.04	0.49	51.64	50.12
Market cap	46.58B	47.48B	57.69B	49.78B	44.65B
Enterprise value	42.22B	83.62B	52.83B	45.3B	37.84B
P/E ratio	21.33	19.43	6.62	-6.6	-2.44
Price to sales ratio	4.13	3.96	4.01	4.51	4.32
POCF ratio	17.55	15.51	-16.25	102.85	17.33
PFCF ratio	24.16	27.33	-14.36	-408.03	23.59
P/B Ratio	1.13	1.22	1.41	1.35	1.34
PTB ratio	1.13	1.22	1.41	1.35	1.34
EV to sales	3.74	6.97	3.67	4.1	3.66
Enterprise value over EBITDA	18.08	31.04	11.93	19.28	26.31
EV to operating cash flow	15.91	27.32	-14.88	93.59	14.69
EV to free cash flow	21.9	48.14	-13.16	-371.3	19.99
Earnings yield	0.01	0.01	0.04	-0.04	-0.1
Free cash flow yield	0.04	0.04	-0.07	0	0.04
Debt to equity	0	1.07	0	1.36	1.45
Debt to assets	0	0.33	0	0.41	0.41
Net debt to EBITDA	-1.87	13.42	-1.1	-1.91	-4.74
Current ratio	1.16	1.08	1.15	1.2	1.13
Interest coverage	1.94	-42.5	6.45	-1.47	-4.34
Income quality	4.81	5.03	-1.63	-0.26	-0.56
Dividend Yield	0	0	0	0.05	0
Payout ratio	0.01	0.02	0	-1.25	0
Sales general and administrative to revenue	0.06	0.06	0.05	0.04	0.05
Research and developement to revenue	0.14	0.13	0.11	0.11	0.15
Intangibles to total assets	0.53	0.51	0.5	0.5	0.49
Capex to operating cash flow	-0.27	-0.43	0.13	-1.25	-0.27
Capex to revenue	-0.06	-0.11	-0.03	-0.05	-0.07
Capex to depreciation	-0.66	-0.72	-0.35	-0.18	-0.14
Stock based compensation to revenue	0	0	0	0	0
Graham number	22.92	23.5	45.55	40.32	59.63
ROIC	0.03	0.01	0.06	-0.01	-0.05
Return on tangible assets	0.01	0.01	0.03	-0.03	-0.08
Graham Net	-75.4	-70.24	-70.53	-71.28	-68.62
Working capital	5.24B	2.68B	5.23B	6.59B	4.45B
Tangible asset value	-27.98B	-24.91B	-21.59B	-23.24B	-23.5B
Net current asset value	-51.13B	-48.19B	-44.41B	-45.77B	-46.17B
Invested capital	0	1.07	0	1.36	1.45
Average receivables	0	0	0	0	0
Average payables	6.32B	7.05B	6.91B	6.12B	6.24B
Average inventory	12.08B	13.19B	13.56B	13.65B	13.86B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	138.78	142.42	98.4	113.88	121.57
Days of inventory on hand	271.06	256.62	212.42	262.64	261.02
Receivables turnover	0	0	0	0	0
Payables turnover	0.65	0.63	0.91	0.79	0.74
Inventory turnover	0.33	0.35	0.42	0.34	0.34
ROE	0.01	0.02	0.05	-0.05	-0.14
Capex per share	-0.74	-1.35	-0.47	-0.62	-0.7

BAYN.DE Dividend History

BAYN.DE Frequently Asked Questions

What is Bayer Aktiengesellschaft stock symbol ?

Bayer Aktiengesellschaft is a DE stock and trading under the symbol BAYN.DE

What is Bayer Aktiengesellschaft stock quote today ?

Bayer Aktiengesellschaft stock price is $31.9 today.

Is Bayer Aktiengesellschaft stock public?

Yes, Bayer Aktiengesellschaft is a publicly traded company.

Something similar

Top by Market Cap

LLY

GOOGL

AAPL

Company Profile

Volume Average 3.7M
Market Capitalization 31.33B
Employee 100.87K
CEO Mr. William N. Anderson
Headquarters Leverkusen,DE
IPO Date 1996-12-16
Website https://www.bayer.com

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.